
Acquisition - May 24, 2019
Amgen to buy Nuevolution for $166.8 million
Amgen has agreed to buy the biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery. Nuevolution said its board unanimously recommended Amgen’s cash offer of 32.5 Swedish crowns per share, a premium of 168.6% to Nuevolution’s closing price on Tuesday, reported Reuters. The offer from Amgen […]